Recital 4, Regulation (EU) 2022/20

In forcesince 7 Jan 2022

Oversight of the safety of active substances used as investigational medicinal products in clinical trials authorised in only one Member State (mono-national active substances), active substances in investigational medicinal products used as a reference, including as a placebo, and active substances used in auxiliary medicinal products should be outside the scope of this Regulation.